OMAHA, Neb.--(BUSINESS WIRE)--Transgenomic, Inc. (OTCBB:TBIO), a global biotechnology company advancing personalized medicine in cardiology, oncology, and inherited diseases through advanced diagnostic tests and clinical and research services, today announced that its shares of common stock have been approved for uplisting to the NASDAQ Capital Market. Effective Friday, May 9, 2014, the stock will trade on NASDAQ under the symbol TBIO.
Help employers find you! Check out all the jobs and post your resume.
